Wenche Stensen

This inventor holds 10 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Lytix Biopharma as, Peptide Patents as, Pharmasum Therapeutics as. Active years: 2007-2023.

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 60.0

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 11(Granted Patents)

Location History:

Kvaloysletta, NO (2013 - 2019)
Kvaløysletta, NO (2007 - 2023)

Company Filing History:

Pharmasum Therapeutics as

patent

Years Active: 2007-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11548912 - Antimicrobial compounds (2023-01-10),

2. 10927106 - Benzothiazole derivatives as DYRK1 inhibitors (2021-02-23),

3. 10231954 - Neurodegenerative therapies (2019-03-19),

4. 9556223 - Antimicrobial compounds (2017-01-31),

5. 9212202 - Methods of peptide modification (2015-12-15),

6. 9115169 - Method of treating tumors (2015-08-25),

7. 9085608 - Treatment of biofilms (2015-07-21),

8. 8598114 - Antimicrobial compounds (2013-12-03),

9. 8048852 - Antimicrobial compounds and formulations (2011-11-01),

10. 7232803 - Antimicrobial compounds and formulations (2007-06-19),

Title: Innovations and Contributions of Inventor Wenche Stensen

Introduction

Wenche Stensen is a notable inventor based in Kvaløysletta, Norway. She has made significant contributions to the field of antimicrobial compounds and neurodegenerative disorder treatments. With a total of 10 patents to her name, her work has the potential to impact various therapeutic areas.

Latest Patents

One of her latest patents involves antimicrobial compounds, which relate to a specific formula designed to inhibit biofilm formation and remove existing biofilms. This invention includes compounds with cationic amino acids and lipophilic R groups, showcasing her innovative approach to therapy. Another significant patent focuses on benzothiazole derivatives as DYRK1 inhibitors, which are aimed at treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, as well as metabolic disorders and cancer.

Career Highlights

Throughout her career, Wenche has worked with several companies, including Lytix Biopharma AS and Peptide Patents AS. Her expertise in the field has allowed her to develop groundbreaking solutions that address critical health issues.

Collaborations

Wenche has collaborated with notable individuals in her field, including John Sigurd Svendsen and Øystein Rekdal. These partnerships have further enhanced her research and development efforts.

Conclusion

Wenche Stensen's innovative work in antimicrobial compounds and neurodegenerative disorder treatments highlights her significant contributions to science and medicine. Her patents reflect a commitment to advancing therapeutic solutions that can improve health outcomes.